| Summary: | 碩士 === 中山醫學大學 === 醫學研究所 === 101 === Objective: Hepatocellular carcinoma (HCC) is a major cause of death for people cancer. Surgery is curative treatment, the recurrence of HCC is still an important factor affecting the prognosis of patients after radical resection, especially the early recurrence of HCC after surgery results in a worse prognosis for patients. Therefore, this study will review the treatment of liver cancer patients receiving liver resection. The early recurrence experience, and analyze the impact of the early risk factors for recurrence.
Methods and Materials: Therefore, this study enrolled the patients with primary HCC who received liver resection in Medical University Hospital. Between June 2010 and December 2012.Retrospective study designs are considered, and use the Cox proportional hazards regression analysis to assess the mechanism of metastasis and recurrence for patients with primary HCC who received liver resection.
Results: Sixty-eight patients who underwent liver resection for HCC were enrolled in this study. During follow-up, twenty-two patients had HCC recurrence, Mean age of these patients at the time of operation was 61.0±5.10 years. The probability of recurrence is 5.32 times normal. The tumor sizes increased by 1 cm, 4-fold increased risk of recurrence. Recurrence rate in patients with vascular invasion is 2.7 times to patients without vascular invasion. Recurrence rate in patients with late AJCC p TNM stage is higher than early stage by 7.5 times. Tumor recurrence rate is 5.61 times in patients who are more intraoperative blood loss. On multivariate analysis, Independent predictors for decreased survival from date of recurrence were (1) preoperative platelet count less than 100,000μL (HR: 9.29；95% CI, 1.34~31.66; P = 0.02), (2) preoperative HCV RNA level than 50-100 million (HR: 1.02；95% CI, 0.78~1.82; P = 0.05).
Conclusion and Suggestion: Our results suggest that close follow-up is mandatory for patients who present with a large tumor burden , Vascular invasion, liver cancer staging the late and preoperative platelet count is low and the amount of HCV RNA patients with blood loss HCC.
|
|---|
